UPLOAD Filing
VERTEX PHARMACEUTICALS INC / MA
Date: April 14, 2026 · CIK: 0000875320 · Accession: 0000000000-26-003732
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
Re: Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2025 File No. 000-19319 Dear Charles F. Wagner Jr.:
April 14, 2026
Charles F. Wagner, Jr. Executive Vice President and Chief Operating & Financial Officer Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston, MA 02210
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
April 14, 2026
Charles F. Wagner, Jr.
Executive Vice President and Chief Operating & Financial Officer
Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston, MA 02210
Re: Vertex Pharmaceuticals, Inc.
Form 10-K for Fiscal Year Ended December 31, 2025
File No. 000-19319
Dear Charles F. Wagner Jr.:
We have completed our review of your filing. We remind you that the
company and its
management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
</TEXT>
</DOCUMENT>